PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma

• Barbara Muz,
• Maurizio Buggio,
• Feda Azab,
• Pilar de la Puente,
• Mark Fiala,
• Mahesh V. Padval,
• David T. Weaver,
• Jonathan A. Pachter,
• Ravi Vij,
• Abdel Kareem Azab

Affiliations

Barbara Muz

Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA

Maurizio Buggio

Nanomedicine Laboratory, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

Feda Azab

Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA

Pilar de la Puente

Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA

Mark Fiala

Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA

Mahesh V. Padval

Verastem Inc., Needham, MA, USA

David T. Weaver

Verastem Inc., Needham, MA, USA

Jonathan A. Pachter

Verastem Inc., Needham, MA, USA

Ravi Vij

Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA

Abdel Kareem Azab

Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA